A Phase I, Open Label Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production When Administered Orally to Obese Insulin-Resistant Adult Subjects for 28 Days.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2011
At a glance
- Drugs HE 3286 (Primary)
- Indications Insulin resistance
- Focus Adverse reactions
- 08 Mar 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 08 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.